News
The ongoing Phase I/IIa study (NCT04725331) is a multicenter, open label, dose-escalation study evaluating BT-001 as a single agent and in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback